Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Aim(s): We investigated the clinical-pathological characteristics, biomarkers of systemic inflammation and therapeutic strategies in a series of NETsG3 and NECs.
Materials and methods: All pts with NETG3 and NEC diagnosed in our institution between 2011 and 2019 were reviewed. The baseline clinical-pathological characteristics, treatment schemes, inflammatory biomarkers and survival of all patients with at least one systemic treatment line were evaluated.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.